Document Detail


Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
MedLine Citation:
PMID:  9400426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: We reviewed the use of percent free prostate specific antigen (PSA) to enhance specificity of PSA testing and aid in the discrimination of benign and malignant prostate disease. We present proposed percent free PSA cut points and probability factors, and discuss factors that are believed to affect study outcomes and conclusions. MATERIALS AND METHODS: We reviewed the literature with respect to PSA and free PSA with particular emphasis on clinical use of percent free PSA and factors that may affect study outcomes. RESULTS: Percent free PSA may increase the specificity of PSA testing without sacrificing the cancer detection rate. Differences in study designs and subject populations may account for the confusion in the current literature. Specific factors that may influence study outcomes include sample size, PSA range, age, race, digital rectal examination findings, prostate size, tumor size and pathology, as well as treatment history, sample collection and storage conditions, and the particular assays used to determine free and total PSA values. CONCLUSIONS: The use of percent free PSA to enhance the specificity of prostate cancer screening is thought to provide useful information to aid in the differentiation of benign and malignant prostate diseases. There is evidence to suggest a benefit cost advantage to a tailored biopsy approach based on percent free PSA. However, statistically valid multisite clinical trials that take into account influencing factors are needed to set assay specific cut points and probability determinations.
Authors:
D L Woodrum; M K Brawer; A W Partin; W J Catalona; P C Southwick
Related Documents :
18625566 - Prostate carcinoma spatial distribution patterns in chinese men investigated with syste...
16906286 - Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in...
8791046 - Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing b...
16140116 - Serum levels of vascular endothelial growth factor in patients undergoing prostate biop...
7510346 - Collagen cross-link metabolites in urine as markers of bone metastases in prostatic car...
24390236 - Missense mutations (p.h371y, p.d438y) in gene chek2 are associated with breast cancer r...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Journal of urology     Volume:  159     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1998 Jan 
Date Detail:
Created Date:  1997-12-29     Completed Date:  1997-12-29     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  5-12     Citation Subset:  AIM; IM    
Affiliation:
Department of Research and Development, Hybritech Incorporated, San Diego, California 92196-9006, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Biopsy
Humans
Male
Palpation
Prostate / pathology
Prostate-Specific Antigen / analysis*
Prostatic Neoplasms / chemistry*,  diagnosis,  pathology
Reference Values
Research
Sensitivity and Specificity
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spinal cord transection--no loss of distal ventral horn neurons. Modern stereological techniques rev...
Next Document:  Historical milestones regarding torsion of the scrotal organs.